Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain

benzinga.com/news/health-care/25/06/46173089/alzheimers-setback-hits-inmune-bio-stock-but-fda-hopes-remain

INmune Bio Inc. (NASDAQ:INMB) stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45 million, as per data from Benzinga Pro.
The company announced results from its Phase 2 MINDFuL trial evaluating XPro, a selective soluble TNF…

This story appeared on benzinga.com, 2025-06-30 15:52:35.
The Entire Business World on a Single Page. Free to Use →